About the Promethera Scientific Medical Advisory Board
The Promethera Scientific Advisory Board is comprised of six independent, renowned and international key opinion leaders in hepatology and liver research. It works closely with Promethera to support its management team and board of directors, providing strategic, scientific and medical advice. Primary key aspects addressed by the SMAB include the application of Promethera’s cell therapy technologies to clinical benefits in a broad range of liver diseases, cell engraftment, cell encapsulation, editing or re-programming of cells, maintenance and expansion of specific cells, clinical translation of certain features of Promethera’s cells to treat liver diseases and the development of relevant small and large animal models.
Massimo Pinzani, MD, PhD, FRCP is a Professor of Medicine, clinical hepatologist, Director of the UCL Institute for Liver and Digestive Health and the Sheila Sherlock Chair of Hepatology at University College of London, UK. He has served in the governing and scientific boards of major international organizations in the areas of hepatology and gastroenterology, and as Associate Editor of top peer reviewed international journals in the area of medicine.
Scientific Medical Advisory Board Members
Anil Dhawan, MD, FRCPCH is a Professor of Paediatric Hepatology, Director of the Paediatric Liver, GI and Nutrition Centre and Clinical Director for Child Health at King’s College Hospital, London, UK. He is Joint Clinical Academic Group (CAG) Leader for Child Health for King’s Health Partners and Director of the Cell Therapy Unit which has pioneered the use of human hepatocytes for the treatment of metabolic liver diseases and acute liver failure.
Sanjeev Gupta, MBBS, MD, FRCP, FACP, FAASLD, is a Professor of Medicine and Pathology and holds the Eleazar and Feige Reicher Chair in Translational Medicine at Albert Einstein College of Medicine in the Bronx, NY, USA. He is a member of several NIH-funded Scientific Centers and Institutes at Albert Einstein College of Medicine. He has served as a keynote speaker in international conferences, is a pioneer of mechanisms to restore the liver by cell transplantation, and has contributed seminal insights in engraftment, proliferation and function of transplanted cells, including stem cell-derived cells, in the liver.
Michael Ott, MD, is Associate Professor for Experimental Hepatology at the Hannover Medical School, Germany which is recognized worldwide as one of the leading centers for transplantation medicine. He specializes in cell and gene therapies for liver diseases, stem cell research, microRNAs and in vitro and in vivo re-programming of somatic cells.
Andreas Nuessler, PhD, is a Professor and Head of Experimental Medicine and Head of the Siegfried Weller Institute within the department of Traumatology at the Eberhard Karls University Tuebingen. He is part-time lecturer in surgery and traumatology. His specific area of research involves various pathways leading to inflammatory reactions in the liver by using isolated liver cells and whole livers. He developed standard culture methods to isolate various fractions of human liver cells for routine use to study specific aspects of drug metabolism in 2D and 3D cultures.
Patrice Cani, RD, MSc, PhD, is a Professor at the Université catholique de Louvain (UCL), Brussels, Belgium, researcher from FRS-FNRS and group leader in the Metabolism and Nutrition lab at the Louvain Drug Research Institute from the UCL. He is WELBIO investigator and co-director of the European Associated Laboratory: “NeuroMicrobiota” (INSERM, Toulouse, France/UCL, Brussels, Belgium).